Predicting cirrhosis in patients with hepatitis C based on standard laboratoiy tests: Results of the HALT-C cohort

Hepatology

Volumn 42, Issue 2, 2005, Pages 282-292

  Lok, Anna S F ^a   Ghany, Marc G ^b   Goodman, Zachary D ^c   Wright, Elizabeth C ^d   Everson, Gregory T ^e   Sterling, Richard K ^f   Everhart, James E ^b   Lindsay, Karen L ^g   Bonkovsky, Herbert L ^h   Di Bisceglie, Adrian M ⁱ   Lee, William M ^j   Morgan, Timothy R ^k   Dienstag, Jules L ^l,m   Morishima, Chihiro ^n,o  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c Veterans Administration   (United States)

^d NEW ENGLAND RESEARCH INSTITUTES   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL FEATURE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; ROC CURVE;

EID: 23044442729     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20772     Document Type: Article

References (37)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
2. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus Statements 2002;19:1-46.
3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). HEPATOLOGY 2000; 32:477-481.
4. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978;74:103-106.
5. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96-98.
6. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. HEPATOLOGY 1994;20:15-20.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:l449-l457.
8. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-48.
9. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15:386-390.
10. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000;95:2328-2332.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
12. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92:1302-1304.
13. Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002;97:2623-2628.
14. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:24l9-2425.
15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38:518-526.
16. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36:986-992.
17. Luo JC, Hwang SJ, Chang FY, Chu CW, Lai CR, Wang YJ, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology 2002;49:478-481.
18. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96: 3142-3146.
19. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol 2001;96:3165-3174.
20. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16:777-781.
21. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.
22. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43: 2156-2159.
23. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023.
24. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated Interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25:472-492.
25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
26. Hosmer DW Lemeshow S. Applied Logistic Regression. Hoboken, NJ: John Wiley & Sons Inc., 1989.
27. Hanley JA McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
28. Aster R. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966;45:645-657.
29. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, Testa E, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003;98:2516-2520.
30. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-1922.
31. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. HEPATOLOGY 1985;5:367-375.
32. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. HEPATOLOGY 1984;4:893-896.
33. Borroni G, Cazzaniga M, Ceriani R, Tommasini MA, Maltempo C, Felline C, et al. Comparison of usefulness and accuracy of simple noninvasive models as predictors of cirrhosis in chronic hepatitis C (CHC). J Hepatol 2004;40(Suppl 1):137 [Abstract].
34. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. HEPATOLOGY 2004;39:862-863 [author reply: 863].
35. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003;38:481-492.
36. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003;49:450-454.
37. Halfon P, Bourliere M, Deydier R, Portal I, Renou C, et al. Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C [Abstract]. HEPATOLOGY 2003;38(Suppl):188A.